Beyond Air Reports Interim Data Of Self-Administered Inhaled NO For Lung Disease

  • Beyond Air Inc (NASDAQ: XAIR) has announced interim data from Australia's ongoing LungFit GO pilot study.

  • Related: Beyond Air Issues Regulatory Update For LungFit PH System.

  • In this study, patients self-administered high concentration inhaled nitric oxide (NO) at home to treat severe nontuberculous mycobacterial (NTM) lung disease.

  • The Company expects complete safety and efficacy results to be reported in 2022.

  • At the data cutoff on September 6, 8 subjects were enrolled in the pilot study.

  • Interim data showed that high concentration inhaled NO was well tolerated with no study discontinuations and no treatment-related serious adverse events.

  • All eight subjects were successfully titrated to 250 ppm NO in the hospital setting, and none have required dose reductions during the subsequent at-home portion of the study.

  • Methemoglobin and NO2 concentrations remained within acceptable ranges in all subjects and below the safety thresholds of 10% and 5 ppm, respectively.

  • Price Action: XAIR shares up 5.30% at $10.22 during the market session on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement